[1] |
Hude I, Sasse S, Engert A,et al.The emerging role of immune checkpoint inhibition in malignant lymphoma[J].Haematologica, 2017,102(1):30-42.
|
[2] |
Usui N.Acute lymphoblastic leukemia/lymphoblastic lymphoma:ALL/LBL[J].Rinsho Ketsueki,2019,60(3):228-229.
|
[3] |
张红玲,白中元,张明星,等.急性T淋巴母细胞淋巴瘤/白血病分子遗传学研究进展[J].中华病理学杂志,2020,49(8):870-873.
|
[4] |
刘卫平.2016修订WHO造血与淋巴组织肿瘤分类:T细胞/NK细胞肿瘤[J].中华病理学杂志,2019,48(1):58-62.
|
[5] |
Young KH.Good prognosis or poor prognosis,dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia[J].Leukemia,2020,34(11): 3075-3076.
|
[6] |
Yang LH, Zhao Y, Maule J,et al.T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classification[J].Br J Haematol,2020,190(5): e307-e312.
|
[7] |
Hayashi RJ, Winter SS, Dunsmore KP,et al.Successful outcomes of newly diagnosed t lymphoblastic lymphoma:results from children′s oncology group AALL0434[J].J Clin Oncol,2020,38(26): 3062-3070.
|
[8] |
Sengar M, Carr R, Jain H, et al. Outcomes of T-lymphoblastic lymphoma treated with pediatric ALL-like protocol[J].Indian J Cancer,2020,57(3): 262-266.
|
[9] |
潘欢,陈晓燕,张婷,等.T淋巴母细胞淋巴瘤/白血病患者PDL1蛋白/mRNA表达及其与临床病理参数和预后的关系[J].疑难病杂志,2019,18(12):1245-1248.
|
[10] |
王浩田,刘苍春,刘利.T淋巴母细胞淋巴瘤的治疗新进展[J].中华血液学杂志,2018,39(11):965-968.
|
[11] |
Heo YA, Syed YY, Keam SJ.Correction to:pegaspargase:a review in acute lymphoblastic leukaemia[J].Drugs,2019,79(7):767-777.
|
[12] |
Blennerhassett R, Kwan J, Coyle L,et al.Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres[J].Br J Haematol,2020,191(2): e58-e60.
|
[13] |
Akahane K, Li Z, Etchin J,et al.Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia[J].Br J Haematol,2017,177(2):271-282.
|
[14] |
Kimura S, Seki M, Yoshida K,et al.NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia[J].Cancer Sci,2019,110(2):784-794.
|
[15] |
Arora PC, Portell CA.Novel therapies for relapsed/refractory mantle cell lymphoma[J].Best Pract Res Clin Haematol,2018,31(1):105-113.
|
[16] |
高建英,党娜,程楠,等.99Tc-甲氧异腈显像在鼻部原发NK/T细胞淋巴瘤中的诊断价值[J/CD].中华诊断学电子杂志,2016,4(1):59-62.
|
[17] |
Yeoh A, Collins A, Fox K, et al. Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia[J].Pediatr Hematol Oncol,2017,34(1):38-42.
|
[18] |
Kim SY, Park JH, Yoon SY,et al.A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia[J].Cancer Chemother Pharmacol,2018,81(2): 393-398.
|
[19] |
Grimes AB, Miller MB, Elghetany MT,et al.A case of a very young child with T lymphoblastic lymphoma with eosinophilia and PDGFRB translocation-a rare form of myeloid/lymphoid neoplasm associated with eosinophilia and rearrangements of PDGFRA,PDGFRB or FGFR1[J].Clin Lymphoma Myeloma Leuk,2020,20(12): e990-e993.
|
[20] |
王菲,王瑞,胡靖,等.儿童白血病中枢神经系统并发症的CT及MRI表现[J].中国实用神经疾病杂志,2020,23(21):1918-1922.
|
[21] |
Lu JP, Wang FX, Wen SP,et al.Haploidentical hematopoietic stem cell transplantation with ′Beijing protocol' in the treatment of T-lymphoblastic lymphoma[J].Leuk Lymphoma,2020,61(11): 2748-2751.
|